ABSTRACT - In recent years, noncomprehensive “guidelines” were proposed for the management of severe acute brain injuries, focusing strictly on two approaches: 1) to maintain cerebral perfusion pressure anywhere above 70 mm Hg; and 2) to maintain arterial carbon dioxide tension levels above 30 torr. Strictly following these propositions, a recently reported prospective controlled study addressed mortality rates of no less than 75-76%, far worse than mortality rates reported before those “guidelines” were published. As a humanitarian alternative, the present comprehensive guidelines are aimed at addressing practical bedside strategies to manage not only intracranial pressure and cerebral perfusion pressure but also cerebral extraction of oxygen, based on solid previously reported papers which revealed the lowest mortality rates (below 15%) in the pertinent literature, in recent years.

KEY WORDS: cerebral extraction of oxygen, intracranial pressure, guidelines, head injury.

Diretrizes práticas e abrangentes para otimização hemometabólica cerebral multiterapêutica

RESUMO - Em anos recentes, “diretrizes” não abrangentes foram propostas para o tratamento de traumatismos cerebrais agudos graves, enfocando estritamente em duas abordagens: 1) manter a pressão de perfusão cerebral em quaisquer níveis acima de 70 mm Hg; e 2) manter a pressão parcial de gás carbônico arterial acima de 30 torr. Seguindo estritamente tais proposições, artigo recentemente publicado envolvendo estudo prospectivo controlado revelou taxas de mortalidade de não menos que 75-76%, muitíssimo piores do que taxas de mortalidade publicadas anteriormente a essas “diretrizes”. Como uma alternativa humanitária, as diretrizes aqui propostas têm como meta explicar estratégias para que se tratem não apenas a pressão intracraniana e a pressão de perfusão cerebral, mas também a extração cerebral de oxigênio, baseando-se em trabalhos sólidos publicados anteriormente, os quais revelaram as menores taxas de mortalidade (inferiores a 15%) da literatura pertinente, em anos recentes.

PALAVRAS-CHAVE: extração cerebral de oxigênio, pressão intracraniana, diretrizes, traumatismo cerebral.

Back in 1996, “guidelines” for the management of severe acute brain injuries were published by several authors and were said to be “evidence-based”. This was not true, however, because no less than four strictly relevant previously published papers were omitted from citation and discussion in those “guidelines”, despite the fact that those four papers had been published in leading international medical journals. Therefore, those “guidelines” were biased and not truly evidence-based, as would have been required in a publication of that kind.

Strictly following those 1996 “guidelines”, a recently published prospective controlled study focusing on the use of induced hypothermia addressed mortality rates of no less than 75-76%, far worse than low mortality rates reported before the aforementioned 1996 “guidelines” were published. In this recent study, routine attempts were made to avoid hyperventilation therapy, maintaining arterial carbon dioxide tension (PCO₂) levels above 30 torr and cerebral perfusion pressure (CPP) anywhere above 70 mm Hg, in addition to frequent mannitol administration and barbiturate therapy for all patients, supplemented by induced hypothermia for the study group.

As a humanitarian alternative to those 1996 “guidelines”, the present practical and comprehensive guidelines address not only treatment of intracranial pressure (ICP) and CPP but also cerebral ex-
ttraction of oxygen (\(\text{CEO}_2\))\(^{2,4,7-12}\). The latter represents the ratio of global cerebral consumption of oxygen (\(\text{CCO}_2\)) to cerebral blood flow (\(\text{CBF}\))\(^8\), and thus provides accurate bedside information regarding coupling or uncoupling between \(\text{CBF}\) and \(\text{CCO}_2\). Adequate \(\text{CBF}-\text{CCO}_2\) coupling, in turn, has already been reported in association with significantly better long-term clinical outcomes from severe acute brain injuries than when a flow-metabolism uncoupling exists during the acute phase of illness\(^9,13\).

Of these two latter studies, the first was based on purely observational (noninterventional) clinical research\(^13\), whereas the second addressed a large prospective controlled trial involving 353 adult patients\(^9\). In the latter series, patients were selected for having predominantly diffuse brain swelling and early intracranial hypertension for both groups, and the use of optimized hyperventilation was conclusively confirmed in association with significantly better long-term clinical outcomes than in the control group, where \(\text{CPP}\) was managed alone (without the use of optimized hyperventilation therapy)\(^9\).

**ICP and \(\text{CPP}\)**

A frequently neglected feature in the management of acute brain injuries is that normal ICP is approximately 5 and 10 mm Hg only for children and adults, respectively. Therefore, the present guidelines propose that elevated ICP levels be aggressively treated so that they are maintained below 15 and 20 mm Hg for children and adults, respectively. Additionally, instead of maintaining \(\text{CPP}\) anywhere above a certain level, the present guidelines propose maintaining \(\text{CPP}\) in the approximate ranges of 50-80 and 60-95 mm Hg for children and adults, respectively.

Indeed, normal-to-increased \(\text{CPP}\) (the difference between mean arterial pressure and mean ICP) has been clearly shown to totally lack any correlation with \(\text{CBF}\), oxygen extraction, and oxygen consumption in severe acute brain injuries\(^8\). This recently reported, striking finding therefore strongly indicated that maintaining high \(\text{CPP}\) levels leads to absolutely no clinical benefit, insofar as physiological optimization is concerned, based on mistaken therapies that iatrogenically increase the blood pressure. Furthermore, as early as 1968, it has been well demonstrated experimentally that arterial hypertension does worsen traumatic brain swelling\(^14\). This original animal study thus suggested that artificially maintaining high \(\text{CPP}\) levels (as proposed in the 1996 “guidelines“) may, in fact, lead to catastrophic consequences when managing brain-injured patients with decreased cerebrospinal fluid spaces and elevated ICP.

**\(\text{CEO}_2\), \(\text{CCO}_2\), and \(\text{CBF}\)**

\(\text{CEO}_2\) is simply the arteriogjugular oxyhemoglobin saturation difference, and represents one of several novel parameters that we have previously proposed for bedside assessment of cerebral hemometabolism\(^2,4,7-12\). Because \(\text{CEO}_2\) is the ratio of \(\text{CCO}_2\) to \(\text{CBF}\), it then becomes clear that \(\text{CCO}_2\) and \(\text{CBF}\) need not be measured, because \(\text{CEO}_2\) alone accurately informs about coupling or uncoupling between \(\text{CBF}\) and \(\text{CCO}_2\).

The normal \(\text{CEO}_2\) ranges are 17-35% and 24-42% for children and adults, respectively\(^2,4,8-12\). For therapeutic purposes, the target values are the normal means of 26% and 33%, respectively. These ranges should be used for therapeutic maintenance (besides maintaining the aforementioned ranges for ICP and \(\text{CPP}\)), whenever possible. Normal-to-increased \(\text{CEO}_2\) values are indicative of relative cerebral hyperperfusion, where \(\text{CBF}\) is reduced relative to \(\text{CCO}_2\). Under these circumstances, attempts should be made to increase \(\text{CBF}\) and decrease \(\text{CEO}_2\), however without compromising adequate ICP control. Conversely, normal-to-decreased \(\text{CEO}_2\) values are indicative of relative cerebral hyperperfusion, where \(\text{CBF}\) is high relative to \(\text{CCO}_2\). Under these circumstances, if ICP is mildly or more markedly elevated, attempts should be made to decrease \(\text{CBF}\) and increase \(\text{CEO}_2\), ideally without exceeding the upper normal \(\text{CEO}_2\) limit.

**Optimized nonbarbiturate sedation**

This is the first step for cerebral hemometabolic optimization, which also allows for adequate mechanical ventilation. In recent years, midazolam has been the most frequently used drug, sometimes in combination with fentanyl for concomitant analgesia. The effects of both drugs on \(\text{CEO}_2\) are not yet known, but their use can be titrated to maintain normal ICP, \(\text{CPP}\), and \(\text{CEO}_2\) as well. The main side effect of this treatment modality is arterial hypotension, which can be reversed by decreasing the administered doses. Expectedly, \(\text{CEO}_2\) could increase if arterial hypotension decreases \(\text{CBF}\) relative to \(\text{CCO}_2\). Conversely, \(\text{CEO}_2\) could also remain normal, because sedation may decrease \(\text{CCO}_2\) as well. Therefore, directly measuring \(\text{CEO}_2\) is the best way of evaluating potential side effects or benefits of nonbarbiturate intravenous sedation.
Optimized mannitol

Because we also monitor CEO₂ (instead of ICP and CPP alone), it then became possible to define an optimal use of intravenous mannitol. This is because, based on ICP alone, the repetitive use of mannitol may lead to hyperosmolality, hypovolemia, and even acute renal failure in extreme cases. Indeed, we have previously reported that the best indication for mannitol is when elevated ICP is associated with normal-to-increased CEO₂ (relative cerebral hyperperfusion)⁷. Under these conditions, fast intravenous mannitol not only lowers elevated ICP but also decreases the CEO₂ toward normal levels, indicative of adequate therapeutic restoration of global CBF-CCO₂ coupling⁷. These positive effects are because, as previously reported¹⁵, CBF does increase following mannitol administration.

The use of nonoptimized mannitol (with normal-to-decreased CEO₂, or relative cerebral hyperperfusion) may also be adopted, but only as long as a sustained benefit regarding ICP control can be confirmed. Nonoptimized mannitol administration should be discontinued if its effect on ICP control lasts less than two hours. The usual mannitol dose for fast intravenous infusion is in the range of 0.4-0.7 g/kg, but higher doses could also be considered, especially in the event that abnormal pupillary widening is found, and/or in preparation for decompressive surgery (see later).

Optimized hyperventilation

Also because we monitor CEO₂ (instead of ICP and CPP alone), it was possible to first propose the use of optimized hyperventilation. The latter is indicated in an opposite fashion to that of optimized mannitol; that is, optimized hyperventilation is used for elevated ICP and normal-to-decreased CEO₂, or relative cerebral hyperperfusion⁷,⁴,⁹-₁². As a general rule, optimized hyperventilation is instituted with arterial (or expired) PCO₂ levels in the approximate range of 20-30 torr, and is implemented for variable periods of no less than 3-4 days. Some patients with more challenging ICP problems will require optimized hyperventilation for longer periods.

According to these standards, when normal ICP levels are achieved, and after at least 4-5 days, PCO₂ values of 30 torr or slightly higher should be gradually restored by slowly reversing the process of optimized hyperventilation, but only as long as normal ICP levels are maintained. In our experience, ICP, CPP, and CEO₂ monitoring and management have lasted approximately 7-10 days for both adults²,⁴,⁹,₁¹ and children¹², according to our comprehensive treatment protocol. This is in sharp contrast to approximately 18 + 13 days reported by those who did not hyperventilate the patients, and iatrogenically induced CPP values anywhere above 70 mm Hg¹⁶.

Optimized barbiturate therapy

Also based on CEO₂ and jugular oxyhemoglobin saturation (SjO₂) monitoring, we¹⁷ first demonstrated that, immediately following intravenous bolus injections of barbiturates for the treatment of elevated ICP refractory to ongoing optimized mannitol and optimized hyperventilation, blood pressure may fall, along with SjO₂ decreases (CEO₂ increases) in some patients. Therefore, caution should be exercised whenever intravenous barbiturate boluses are administered for ICP control, and the use of vasopressor drugs should be immediately instituted if necessary.

The usual barbiturate dose (pentobarbital or thiopental) is approximately 15 mg/kg for the loading dose over 60-90 minutes, followed by approximately 1.5-2 mg/kg/hour for the maintenance dose. With normal and stable ICP levels for at least 24 hours, the cumulative use of optimized mannitol, optimized hyperventilation, and optimized barbiturate therapy can then be gradually discontinued in the reverse order of implementation, starting with barbiturate discontinuation. The latter is usually accomplished by decreasing the infusion dose by 50% at intervals of approximately 6 hours. Discontinuing the cumulative treatment protocol¹⁹-₁² should be considered no earlier than at least 4-5 days after the start of treatment. When instituting barbiturate therapy if necessary, it is obvious that the first step of the protocol (nonbarbiturate intravenous sedation) should be discontinued.

Decompressive surgery

Having optimized and maximized the above-described nonsurgical cumulative treatment protocol, as gradually or rapidly as required by less or more challenging ICP problems, decompressive surgery should then be considered for refractory intracranial hypertension (ideally before ICP exceeds 30 mm Hg). The choice of external versus internal decompression depends on the presence or absence of brain areas that are presumably unviable (e.g., hemorrhagic contusions), as well as the neurosurgeon’s experience. We have successfully adopted decompressive surgery¹³,¹₂,¹₈,¹₉ as the final step in the cu-
cumulative treatment protocol that we developed over the years, and for a large number of patients.

**Comparative clinical outcomes**

According to our previously reported treatment protocol, the best mortality rates have ranged from 9% (for comatose adult patients with predominantly traumatic diffuse brain swelling)\(^9\) to 14% (for comatose adult patients with acute subdural hematomas and postoperative brain swelling)\(^11\). For selected children in acute coma with traumatic intracranial hypertension, our treatment protocol was associated with a mortality rate of 4% only\(^12\). These figures are in sharp contrast to 75-76% mortality rates\(^6\) reported for adult patients treated according to the above-mentioned 1996 “guidelines”\(^1\), and strongly indicate that our presently proposed comprehensive guidelines are far more humanitarian and clinically sound than any other previously reported.

**Abandoning brain tissue probes**

A recent study\(^20\) involving sophisticated noninvasive positron emission tomography has definitively ruled out the occurrence of regional brain ischemia following hyperventilation therapy, a finding in full agreement with our previously reported global (arteriojugular) measurements involving both oxygen and glucose extraction\(^2,4\). Indeed, we have also recently reported that global brain ischemia is absolutely rare in acute brain trauma, as evaluated by simultaneous arteriojugular oxygen and lactate differences\(^11\).

Despite the above-mentioned findings, an alternative monitoring “modality” involving acute placement of brain tissue probes to evaluate focal oxygen tension\(^21\) has claimed that hyperventilation is harmful. In this recent paper\(^21\), the authors found that even when the jugular catheter showed high cerebral venous oxygenation, hyperventilation dropped the brain tissue oxygen tension to so-called “critically low” levels. In this respect, however, it is well known that acute placement of brain tissue probes causes focal microvascular compression and distortion, besides focal blood-brain barrier disruption (because the probes are too stiff relative to the soft brain tissue).

Therefore, it is not surprising that brain tissue probes will almost invariably show low oxygen values, which are, nevertheless, just focal and artificial relative to the global brain. The latter is better evaluated by techniques where the brain tissue is not invaded (e.g., jugular measurements or positron emission tomography). Furthermore, because healthy human beings will just never volunteer to have their heads open for any brain tissue probe to be placed, normal physiological values for these probes designed for any “measurement” (e.g., microdialysis, oxygen tension, temperature, etc) are not even known, and most likely will never be known. Therefore, “critical” values for any element measured by these focal brain tissue probes represent speculation and misinformation, at least until otherwise proven.

Because normal physiological values are not even known, and because these focal brain tissue probes are highly invasive, their use can be regarded as gross animal experimentation in humans\(^21,23\), which should therefore be abandoned and eventually punished, rather than being commercially and industrially promoted.

**Future prospects**

Because a variety of acute intracranial insults (besides brain trauma) may be frequently associated with combined abnormalities regarding ICP, CPP, and CEO\(_2\), Table 1 shows a broad spectrum of acute intracranial disease processes in which our proposed monitoring and protocol could also be explored. It is hoped that this comprehensive, practical, and inexpensive monitoring and treatment protocol will also help lowering mortality rates in acute intracranial events other than acute severe brain trauma.

---

**Table 1. Indications for arteriojugular monitoring and management.**

| 1 | Severe acute brain trauma with suspected or confirmed intracranial hypertension; |
| 2 | Some forms of nontraumatic intracranial hemorrhage with suspected or confirmed intracranial hypertension; |
| 3 | Hepatic encephalopathy with suspected or confirmed intracranial hypertension; |
| 4 | Uremic encephalopathy with suspected or confirmed intracranial hypertension; |
| 5 | Near-drowning with suspected or confirmed intracranial hypertension; |
| 6 | Posthypoxic encephalopathy with suspected or confirmed intracranial hypertension; |
| 7 | Meningitis or meningoencephalitis with suspected or confirmed intracranial hypertension; |
| 8 | Hypertensive encephalopathy (including eclamptic encephalopathy) with suspected or confirmed intracranial hypertension; |
| 9 | Septic encephalopathy with suspected or confirmed intracranial hypertension |
REFERENCES


